Valerio Therapeutics Société anonyme (ALVIO.PA)
EUR 0.07
(-1.2%)
EUR 0.07
(-1.2%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.00 EUR | -100.0% |
| 2022 | 744 Thousand EUR | -48.73% |
| 2021 | 1.45 Million EUR | 0.0% |
| 2020 | - EUR | -100.0% |
| 2019 | 64 Thousand EUR | 36.17% |
| 2018 | 47 Thousand EUR | 56.67% |
| 2017 | 30 Thousand EUR | -83.7% |
| 2016 | 184 Thousand EUR | 73.58% |
| 2015 | 106 Thousand EUR | 62.65% |
| 2014 | 65.17 Thousand EUR | 1972.21% |
| 2013 | 3145.00 EUR | 14.82% |
| 2012 | 2739.00 EUR | 89.68% |
| 2011 | 1444.00 EUR | -96.17% |
| 2010 | 37.72 Thousand EUR | 78.35% |
| 2009 | 21.15 Thousand EUR | -17.2% |
| 2008 | 25.54 Thousand EUR | -87.92% |
| 2007 | 211.52 Thousand EUR | 240.59% |
| 2006 | 62.1 Thousand EUR | 0.0% |
| 2005 | - EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - EUR | -100.0% |
| 2024 Q2 | -3.33 Million EUR | 0.0% |
| 2023 Q4 | 1.00 EUR | 0.0% |
| 2023 Q3 | 1.00 EUR | -100.0% |
| 2023 FY | 1.00 EUR | -100.0% |
| 2023 Q2 | 2.19 Million EUR | 0.0% |
| 2023 Q1 | - EUR | -100.0% |
| 2022 Q1 | 1.00 EUR | 0.0% |
| 2022 FY | 744 Thousand EUR | -48.73% |
| 2022 Q4 | 744 Thousand EUR | 0.0% |
| 2022 Q3 | - EUR | -100.0% |
| 2022 Q2 | 1.00 EUR | 0.0% |
| 2021 FY | 1.45 Million EUR | 0.0% |
| 2021 Q1 | - EUR | 0.0% |
| 2021 Q3 | 1.00 EUR | 0.0% |
| 2021 Q4 | 1.00 EUR | 0.0% |
| 2021 Q2 | 1.00 EUR | 0.0% |
| 2020 Q3 | - EUR | 0.0% |
| 2020 Q2 | - EUR | 0.0% |
| 2020 Q4 | - EUR | 0.0% |
| 2020 FY | - EUR | -100.0% |
| 2020 Q1 | - EUR | -100.0% |
| 2019 Q1 | 58 Thousand EUR | 23.4% |
| 2019 FY | 64 Thousand EUR | 36.17% |
| 2019 Q4 | 64 Thousand EUR | 0.0% |
| 2019 Q3 | 64 Thousand EUR | 10.34% |
| 2019 Q2 | 58 Thousand EUR | 0.0% |
| 2018 Q1 | 33 Thousand EUR | 10.0% |
| 2018 Q2 | 33 Thousand EUR | 0.0% |
| 2018 Q3 | 47 Thousand EUR | 42.42% |
| 2018 Q4 | 47 Thousand EUR | 0.0% |
| 2018 FY | 47 Thousand EUR | 56.67% |
| 2017 Q1 | 18 Thousand EUR | -90.22% |
| 2017 FY | 30 Thousand EUR | -83.7% |
| 2017 Q4 | 30 Thousand EUR | 0.0% |
| 2017 Q3 | 30 Thousand EUR | 66.67% |
| 2017 Q2 | 18 Thousand EUR | 0.0% |
| 2016 FY | 184 Thousand EUR | 73.58% |
| 2016 Q3 | 184 Thousand EUR | 142.11% |
| 2016 Q2 | 76 Thousand EUR | 0.0% |
| 2016 Q1 | 76 Thousand EUR | -28.3% |
| 2016 Q4 | 184 Thousand EUR | 0.0% |
| 2015 Q2 | 22.14 Thousand EUR | 0.0% |
| 2015 Q4 | 106 Thousand EUR | 0.0% |
| 2015 FY | 106 Thousand EUR | 62.65% |
| 2015 Q1 | 22.14 Thousand EUR | -66.03% |
| 2015 Q3 | 106 Thousand EUR | 378.77% |
| 2014 Q3 | 65 Thousand EUR | 2636.84% |
| 2014 Q4 | 65.17 Thousand EUR | 0.26% |
| 2014 Q2 | 2375.00 EUR | 0.0% |
| 2014 FY | 65.17 Thousand EUR | 1972.21% |
| 2014 Q1 | 2375.00 EUR | -24.48% |
| 2013 Q4 | 3145.00 EUR | 0.0% |
| 2013 FY | 3145.00 EUR | 14.82% |
| 2013 Q3 | 3145.00 EUR | 18.95% |
| 2013 Q2 | 2644.00 EUR | 0.0% |
| 2013 Q1 | 2644.00 EUR | -3.47% |
| 2012 FY | 2739.00 EUR | 89.68% |
| 2012 Q2 | 11.85 Thousand EUR | 0.0% |
| 2012 Q4 | 2739.00 EUR | 0.0% |
| 2011 Q4 | 1444.00 EUR | 0.0% |
| 2011 FY | 1444.00 EUR | -96.17% |
| 2011 Q2 | 1573.00 EUR | 0.0% |
| 2010 FY | 37.72 Thousand EUR | 78.35% |
| 2010 Q4 | 37.72 Thousand EUR | 0.0% |
| 2010 Q2 | 19.43 Thousand EUR | 0.0% |
| 2009 Q4 | 21.15 Thousand EUR | 0.0% |
| 2009 FY | 21.15 Thousand EUR | -17.2% |
| 2008 FY | 25.54 Thousand EUR | -87.92% |
| 2007 FY | 211.52 Thousand EUR | 240.59% |
| 2006 FY | 62.1 Thousand EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ABIONYX Pharma SA | 221 Thousand EUR | 100.0% |
| ABIVAX Société Anonyme | 1.00 EUR | 0.0% |
| Adocia SA | 272 Thousand EUR | 100.0% |
| Aelis Farma SA | 53 Thousand EUR | 99.998% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 1.74 Million EUR | 100.0% |
| genOway Société anonyme | 982.75 Thousand EUR | 100.0% |
| IntegraGen SA | 311.44 Thousand EUR | 100.0% |
| Medesis Pharma S.A. | 164.62 Thousand EUR | 99.999% |
| Neovacs S.A. | - EUR | -Infinity% |
| NFL Biosciences SA | -1.1 Million EUR | 100.0% |
| Plant Advanced Technologies SA | 1.22 Million EUR | 100.0% |
| Quantum Genomics Société Anonyme | -119.17 Thousand EUR | 100.001% |
| Sensorion SA | - EUR | -Infinity% |
| Theranexus Société Anonyme | - EUR | -Infinity% |
| TME Pharma N.V. | 91 Thousand EUR | 99.999% |
| Valbiotis SA | 1 Million EUR | 100.0% |
| TheraVet SA | 123.34 Thousand EUR | 99.999% |
| DBV Technologies S.A. | 1.00 USD | 0.0% |
| Genfit S.A. | 4000.00 EUR | 99.975% |
| GeNeuro SA | - EUR | -Infinity% |
| Innate Pharma S.A. | 1.00 EUR | 0.0% |
| Inventiva S.A. | 417 Thousand EUR | 100.0% |
| MaaT Pharma SA | 190 Thousand EUR | 99.999% |
| MedinCell S.A. | -6.71 Million EUR | 100.0% |
| Nanobiotix S.A. | 200 Thousand EUR | 100.0% |
| OSE Immunotherapeutics SA | - EUR | -Infinity% |
| Poxel S.A. | 2.95 Million EUR | 100.0% |
| GenSight Biologics S.A. | 1.00 EUR | 0.0% |
| Transgene SA | - EUR | -Infinity% |
| Valneva SE | 44.46 Million EUR | 100.0% |